paclitaxel
Start here
Adding intravenous VCN-01, a hyaluronidase-expressing oncolytic adenovirus, to gemcitabine and nab-paclitaxel improved outcomes as first-line therapy in metastatic pancreatic ductal adenocarcinoma. In the full analysis set, median overall survival was 10.8 versus 8.6 months (HR 0.57) and progression-free survival was 7.0 versus 4.6 months (HR 0.55, P = 0.011); response duration was 11.2 versus 5.4 months. The phase 3 evaluation is warranted.
Excerpted from Nat Med
Coverage timeline
Follow the coverage to see the different angles.
- clinicaltrials.govMRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
- Nat MedPickIntravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.
Adding intravenous VCN-01, a hyaluronidase-expressing oncolytic adenovirus, to gemcitabine and nab-paclitaxel improved outcomes as first-line therapy in metastatic pancreatic ductal adenocarcinoma. In the full analysis set, median overall survival was 10.8 versus 8.6 months (HR 0.57) and progression-free survival was 7.0 versus 4.6 months (HR 0.55, P = 0.011); response duration was 11.2 versus 5.4 months. The phase 3 evaluation is warranted.
- mp.weixin.qq.comPickNMPA Approves Paclitaxel Oral Solution Bairuisu for HER2-Negative Breast Cancer
On September 29, 2026, the NMPA approved the breast cancer indication for paclitaxel oral solution (brand name Bairuisu), a product of 3SBio and Shanghai Haihe Pharmaceutical, for recurrent or metastatic HER2-negative breast cancer. The drug, the first oral paclitaxel formulation worldwide, was previously approved in September 2024 as second-line treatment for advanced gastric cancer. Its use now extends from gastric to breast cancer, offering an oral option for a chemotherapy long given only by injection.
Heat trend for this story
Heat now 86·Peak in the comparable set 99 (Oct 25 07:00)·Change over 24h in the comparable set +1726%·Participants now 15
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.